A compound is disclosed. The compound has a formula of MA.sub.xL.sub.y, wherein: A is

##STR00001## L is one of

##STR00002## M is a metal having six valence electrons, x is an integer from 1-3, y is an integer from 0-2, x+y=3, any of R.sub.a-R.sub.b and R.sub.1-R.sub.3 is independently selected from a group consisting of hydrogen, deuterium, fluorine, chlorine, bromine, iodine, N(R.sup.1).sub.2, N(Ar.sup.1).sub.2, C(O)Ar.sup.2, P(O)Ar.sup.3.sub.2, S(O)Ar.sup.4, S(O).sub.2Ar.sup.5, CR.sup.2CR.sup.3Ar.sup.6, CN, NO.sub.2, Si(R.sup.4).sub.3, B(OR.sup.5).sub.2, OSO.sub.2R.sup.6, a linear alkyl having 1 to 40 carbon atoms, a C.sub.1-C.sub.40 alkoxyl, a C.sub.1-C.sub.40 alkylthiol, a C.sub.3-C.sub.40 branched alkyl, a C.sub.3-C.sub.40 cycloalkyl, a C.sub.3-C.sub.40 branched alkoxyl, a C.sub.3-C.sub.40 cyclic alkoxyl, a C.sub.3-C.sub.40 branched alkylthiol and a C.sub.3-C.sub.40 cyclic alkylthiol, any of R.sup.1-R.sup.6 is one of a hydrogen and an alkyl, any of Ar.sup.1-Ar.sup.6 is one of a hydrogen and an aryl, and any of R.sub.4R.sub.11 and R.sub.13R.sub.15 is independently selected from a group consisting of a hydrogen, a deuterium, a halogen, a substituted or unsubstituted alkyl, a substituted or unsubstituted cycloalkyl and a substituted or unsubstituted aryl.

Objects of the present invention are to provide an industrially applicable method for producing an optically active -amino acid in high yield and in a highly enantioselective manner, to provide a simple production method of an optically active ,-disubstituted -amino acid, and to provide an intermediate useful for the above production methods of an optically active -amino acid and an optically active ,-disubstituted -amino acid. The present invention provides a production method of an optically active -amino acid or a salt thereof, the production method comprising introducing a substituent into the carbon in the -amino acid moiety of a metal complex represented by the following Formula (1): ##STR00001##
by an alkylation reaction, an aldol reaction, the Michael reaction, or the Mannich reaction, and releasing an optically pure -amino acid enantiomer or a salt thereof by acid decomposition of the metal complex.

Objects of the present invention are to provide an industrially applicable method for producing an optically active -amino acid in high yield and in a highly enantioselective manner, to provide a simple production method of an optically active ,-disubstituted -amino acid, and to provide an intermediate useful for the above production methods of an optically active -amino acid and an optically active ,-disubstituted -amino acid. The present invention provides a production method of an optically active -amino acid or a salt thereof, the production method comprising introducing a substituent into the carbon in the -amino acid moiety of a metal complex represented by the following Formula (1): ##STR00001##
by an alkylation reaction, an aldol reaction, the Michael reaction, or the Mannich reaction, and releasing an optically pure -amino acid enantiomer or a salt thereof by acid decomposition of the metal complex.

An object of the present invention is to provide a method for producing an optically active amino acid in high yield and in a highly enantioselective manner, which method has fewer restrictions on the material that can be used as the substrate, and to provide, among others, a compound useful as a chiral auxiliary for the method. The present invention provides an N-(2-acylaryl)-2-[5,7-dihydro-6H-dibenzo[c,e]azepin-6-yl]acetamide compound represented by Formula (1): ##STR00001##
or a salt thereof, or a metal complex represented, by Formula (3): ##STR00002##

An object of the present invention is to provide a method for producing an optically active amino acid in high yield and in a highly enantioselective manner, which method has fewer restrictions on the material that can be used as the substrate, and to provide, among others, a compound useful as a chiral auxiliary for the method. The present invention provides an N-(2-acylaryl)-2-[5,7-dihydro-6H-dibenzo[c,e]azepin-6-yl]acetamide compound represented by Formula (1): ##STR00001##
or a salt thereof, or a metal complex represented, by Formula (3): ##STR00002##

Provided are compositions and methods useful for modulation of signaling through the Toll-like receptors TLR7 and/or TLR8. The compositions and methods have use in treating or preventing disease, including cancer, autoimmune disease, infectious disease, inflammatory disorder, graft rejection, and graft-versus-host disease.

Provided are compositions and methods useful for modulation of signaling through the Toll-like receptors TLR7 and/or TLR8. The compositions and methods have use in treating or preventing disease, including cancer, autoimmune disease, infectious disease, inflammatory disorder, graft rejection, and graft-versus-host disease.

Compounds of Formula I and their uses of effective AXL inhibitors and for the treatment of physical condition mediated by AXL.

##STR00001##

The invention relates to compounds of general formula (I) wherein R.sub.1, R.sub.2, R.sub.3, R.sub.4, m and n are defined as defined herein, and pharmaceutically acceptable salts, hydrates, or solvates thereof, for usealone or in combination with one or more other pharmaceutically active compoundsin therapy, as JAK kinase and protein tyrosine kinase inhibitors for preventing, treating or ameliorating diseases and complications thereof, including, for example, psoriasis, atopic dermatitis, rosacea, lupus, multiple sclerosis, rheumatoid arthritis, Type I diabetes, asthma, cancer, autoimmune thyroid disorders, ulcerative colitis, Crohn's disease, Alzheimer's disease, leukaemia, eye diseases such as diabetic retinopathy and macular degeneration as well as other autoimmune diseases and indications where immuno-suppression would be desirable for example in organ transplantation. ##STR00001##

The present invention is directed to a compound represented by Structural Formula (I):

##STR00001##

or a pharmaceutically acceptable salt thereof. The variables for Structural Formula I are defined herein.

Also described is a pharmaceutical composition comprising the compound of Structural Formula I and its therapeutic use.